Harness the Dual Benefits of Freshly Isolated Plateability and the Efficiencies of Cryopreservation
CHICAGO, June 16 /PRNewswire/ -- In today's competitive environment and economic climate, the financial implications of being the first to file a promising new drug compound or chemical entity cannot be underestimated. Researchers and drug manufacturers are under even greater pressure to do more with less, and productivity and cost savings are at a premium. In the race to succeed, fresh hepatocytes (cells that mimic the properties of the liver and are used by researchers to evaluate the metabolism, drug-drug interaction and toxicity of drug candidates in a cost-effective manner) present a number of challenges.
Celsis International plc (LSE: CEL.L) - a leading global provider of innovative life science products and laboratory services to the pharmaceutical, biopharmaceutical and consumer products industries - outlines several key advantages of using cryopreserved plateable hepatocytes over fresh tissue for drug research.
|SOURCE Celsis International plc|
Copyright©2009 PR Newswire.
All rights reserved